Summary & Overview
HCPCS Level II Q5132: Adalimumab-afzb (Abrilada) 10 mg Injection
HCPCS Level II code Q5132 designates the 10 mg injection of adalimumab-afzb (Abrilada), a biosimilar to adalimumab used in outpatient biologic therapy. Its presence in the HCPCS Level II file enables facilities and clinicians to bill for the specific biosimilar product and supports product-level tracking, formulary management, and payer coverage determinations. Nationally, biosimilar codes like Q5132 matter for cost management and for monitoring uptake of lower-cost biologic alternatives.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find benchmarks and coverage context for billing Q5132, guidance on typical sites of service and service type, and a summary of common billing modifiers and reporting considerations. The publication also outlines clinical context for adalimumab biosimilars and how the HCPCS Level II designation affects coding workflows and payer adjudication. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code Q5132 represents an injection of adalimumab-afzb (Abrilada), a biosimilar formulation, in a 10 mg dosage. This code describes the drug administration item itself and is used for billing the specific biosimilar product rather than the reference biologic.
Service Type: Drug injection (biosimilar)
Typical Site of Service: Outpatient infusion/clinic, physician office, or other outpatient administration settings
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with an immune-mediated inflammatory disease such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or plaque psoriasis who requires subcutaneous biologic therapy. The patient presents to an infusion or injection clinic, specialty pharmacy clinic, or office-based procedure room for administration of a biosimilar adalimumab product. The service documented by Q5132 represents a 10 mg prefilled-syringe or pen dose of adalimumab-afzb (Abrilada) used for subcutaneous injection.
The clinical workflow includes verification of the medication order and dose, allergy and infection screening, patient education regarding self-administration if discharge to home is planned, preparation of the injection by a licensed clinician or trained staff, administration via subcutaneous injection, and post-injection observation for adverse reactions. Documentation includes medication lot and expiration, administration site, route, dose, informed consent or teaching, and any immediate adverse effects. Billing uses Q5132 to report the specific HCPCS Level II supply for the 10 mg adalimumab-afzb product when applicable per payer guidance.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased Procedural Services |